Form D · Biotechnology
Conexeu Sciences Inc.
Reno, NV · CIK 0002066836
Offering snapshot reported Oct 21, 2026 · SEC filing
- Reported sold
- $1.5M Offering amount: $3M
- Investors reported
- 2 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Oct 15, 2026 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Oct 21, 2026 | Initial | $1,499,997 | No comparison | 2 | SEC filing |
| Sep 29, 2026 | Initial | $30,875 | No comparison | 2 | SEC filing |
| Sep 15, 2026 | Initial | $252,148 | No comparison | 2 | SEC filing |
| Aug 31, 2026 | Initial | $88,548 | No comparison | 3 | SEC filing |
| Jul 31, 2026 | Initial | $62,725 | No comparison | 2 | SEC filing |
| Jun 30, 2026 | Initial | $86,320 | No comparison | 2 | SEC filing |
| Jun 30, 2026 | Initial | $203 | No comparison | 1 | SEC filing |
| Jun 12, 2026 | Amendment | $1,700 | $500vs Jun 13, 2025 | 3 | SEC filing |
| Jun 10, 2026 | Initial | $22,905 | No comparison | 1 | SEC filing |
| May 21, 2026 | Initial | $543 | No comparison | 3 | SEC filing |
| May 21, 2026 | Initial | $44,700 | No comparison | 1 | SEC filing |
| Apr 1, 2026 | Initial | $1,815,000 | No comparison | 8 | SEC filing |
| Mar 23, 2026 | Initial | $44,698 | No comparison | 1 | SEC filing |
| Feb 27, 2026 | Initial | $467 | No comparison | 7 | SEC filing |
| Feb 4, 2026 | Initial | $810,000 | No comparison | 1 | SEC filing |
| Nov 20, 2025 | Initial | $202,299 | No comparison | 7 | SEC filing |
| Nov 13, 2025 | Initial | $2,921,446 | No comparison | 5 | SEC filing |
| Jul 2, 2025 | Amendment | $1,287,329 | $0vs May 9, 2025 | 18 | SEC filing |
| Jun 13, 2025 | Initial | $1,200 | No comparison | 2 | SEC filing |
| May 9, 2025 | Initial | $1,287,329 | No comparison | 18 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- Yes
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-601951
Total Offering Amount equals the price of units (499,999 units @ $3.00), plus aggregate exercise price of the warrants forming part of the units (499,999 warrants @ $3.00).
Source: Form D, filed Oct 21, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No matching detailed fund disclosure was found in the latest imported ADV filings. This does not establish that the issuer has no adviser.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Ana Bastiani Posner | Director |
| David R Bogart | Director, Executive |
| April Burke | Director |
| Claudia Chavez Munoz | Executive |
| Andrew Costa | Director |
| Aaron Farberg | Director |
| Miles Harrison | Director, Executive |
| Stephen D Inouye | Executive |
| Z Paul Lorenc | Director |
| Brian Pilcher | Executive |
| Sebastian Purcell | Director |
| Jeff Sharpe | Director |
| Claudia Stephen | Executive |
| Michael Wright | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
50 West Liberty Street, Suite 880
Reno, NV, 89501
Phone: 424-333-5622
Reno, NV, 89501
Phone: 424-333-5622